15% rise in two days and probably more to come. Any disillusioned followers should take another look.

Hope you're paying attention. Up 12.5% today.

drum...probably everyone who knows this lot well is paying attention but, to what......?

We need NEWS!!
Good solid stuff to hoist the price back to the mid 1-2 where long termers like myself are convinced it belongs as a minimum.

From there with further good news and results the world should be our lobster!

Somebody must know why! Up another 5% this morning.

I bought in a week ago @63-66 looks good for a bounce looking at the charts it has broken downtrend. Stop in @69

In the Mail Today
Start of the big rise?

Is there only me buying these?

Fillyer boots nobody wants these at 74p or above. newspaper reveiws pending deals, what about some positive news flow from the company - then it may hit 80p and above till then not a great deal of movement.

Proteome in Tandem with mystery partner
Published: 11:21 Friday 01 April 2005
By: Douglas Bence, Companies Correspondent

Shares in AIM-listed Proteome Sciences raced ahead on news that the Surrey-based company is about to sign an exclusive licensing deal with a 'major global healthcare player' for its Tandem Mass Tags, reagents used in protein research.

When the deal is signed Proteome (PRM) will receive $2.3 million (1.2 million) in milestone payments and a signing on fee.

Royalty payments will be in double digits, the company said in a trading statement, unusually high for the healthcare market.

The shares added 12p to 71.5p, a rise of 20.17% with four times the usual daily number changing hands in the first two hours trading.

Although Heads of Agreement have been signed and negotiations are advanced, no further details are being released and the partner remains unidentified.

The company has also completed its first deal with Regen Therapeutics involving Colostrinin, a proline-rich polypeptide complex derived from bovine colostrums, which is being developed for veterinary use.

Colostrinin, or small molecular weight compounds based on them, may have potential as pharmaceutical agents for the treatment of Alzheimer's and other
neurodegenerative diseases.

Proteome Sciences has recently raised 4.7 million with a share placing of 8 million new shares at 59.5p with an institution, 6.6% of the equity.

Chief executive Christopher Pearce is also putting an additional 255,000 into the company by exercising warrants.

Proteomics is the study of proteins and may eventually help the big pharmaceutical groups overcome the major clinical problems they suffered towards the end of last year.

It has three key applications: diagnosis, prognosis and therapy. Research to date has concentrated on proteins relating to neurological diseases, cancer, rejection after organ transplantation, diabetes and obesity.

Proteins change in certain disease conditions; they become elevated or de-elevated. If they can be identified as Protein Markers they can enable doctors to diagnose diseases.

When drugs to patients are administered, protein change can be measured with blood tests to help with a prognosis to see how effective the prescribed therapy is.

Pearce believes proteomics will lead to proteins themselves being developed as therapies.

He said: 'With the current problems with drugs in development a different approach to clinical risk management is necessary for new regulatory requirements. We believe that proteomics technology will be one of the major contributors and beneficiaries of this'.

Citywire Verdict: A year ago the shares were 193.5p; last month they bottomed at 54.5p. The placing price of 59.5p may be significant. With today's 20% plus increase, those looking for quick profits may be too late. If you believe in the future of proteomics, and it is difficult not to, buy now and sit tight for two years.

http://www.citywire.co.uk/News/NewsArticle.aspx?VersionID=73219&MenuKey=News.Home&NewsPage=4

Been watching these for a while and I think now is the time to pile in. SP will be onwards and upwards especially as there has already been a placing and the director is also putting in 255k.

Could not agree more was buying these when all was selling. sitting on a nice profit already but not selling any before 2 by christmas

.

:-)

.

Just out.

Proteome Sciences plc ('the Company')

Proteome Sciences plc was today advised that as at the close of business on 8
April 2005, Man Financial Limited had a notifiable interest in 5,323,500
ordinary shares in the Company, representing 4.05% of its current issued
ordinary share capital.


So Is that an Increase or decrease In Man's holding, does anyone know please?

increase

Thanks LL.

anyone know why the rise

No posts on PRM here today even with Advfn down?

Maybe it's not so over-hyped as people think ;o) Nice chart recently, would be good to see confirmed breakout alongside deal news. Can't be far away now.

bluemango
I think this will explode when the 1st deal is in the bag. Lot of hot money will pile in then. As a future long term holder i ham happy to sit back and watch. Have been spread betting these for fun as ,(long) of course
Good luck all
Dave

Leedslad - you may be right about 'hot money' piling in when the deals come, but I also think a lot of investors/long termers are as well waiting for that certainty before getting back in or adding. Eg saw the following comment posted just this morning on another bb:

"i think i will wait and pay a premium after any news. this is the safer option imho. i've bought into prm before on big deal rumours only to be disappointed. i would rather buy post deal."

Major institutional buying will also probably only come when we have tangible evidence of cash flowing in the company in the form of upfronts etc, so far Fidelity have been about the only ones prepared to take the risk beforehand.

PRM are I think still suffering from 'CJP promises fatigue', with investors/traders having the attitude of 'I'll believe it when I see it'. But I think a fairly large proportion of the 131m shares in issue are very tightly held at this point, which should provide a supply squeeze and subsequent strong rise when the deals are confirmed.